PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALY

Authors:
  • IAI. Agirrezabal
    I. Agirrezabal
  • IGI. Gaikwad
    I. Gaikwad
  • LCL. Cirillo
    L. Cirillo
  • MLM. Lothgren
    M. Lothgren

Abstract
No abstract available